Dietary Omega Polyunsaturated Fatty Acid Intake and Patient-Reported Outcomes in Systemic Lupus Erythematosus: The Michigan Lupus Epidemiology and Surveillance Program

被引:28
|
作者
Charoenwoodhipong, Prae [1 ]
Harlow, Sioban D. [1 ]
Marder, Wendy [1 ]
Hassett, Afton L. [1 ]
McCune, W. Joseph [1 ]
Gordon, Caroline [2 ]
Helmick, Charles G. [3 ]
Barbour, Kamil E. [3 ]
Wang, Lu [1 ]
Mancuso, Peter [1 ]
Somers, Emily C. [1 ]
Zick, Suzanna M. [1 ]
机构
[1] Univ Michigan, Ann Arbor, MI 48109 USA
[2] Univ Birmingham, Birmingham, W Midlands, England
[3] Ctr Dis Control & Prevent, Atlanta, GA USA
关键词
DISEASE-ACTIVITY; SLEEP; SUPPLEMENTATION; FIBROMYALGIA; VALIDATION; PROTECTINS; RESOLVINS; CRITERIA; QUALITY; TRIAL;
D O I
10.1002/acr.23925
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective To examine associations between dietary intake of omega-3 (n-3; generally antiinflammatory) and omega-6 (n-6; generally proinflammatory) fatty acids and patient-reported outcomes in systemic lupus erythematosus (SLE). Methods This study was based on the population-based Michigan Lupus Epidemiology and Surveillance cohort. Estimates of n-3 and n-6 intake were derived from Diet History Questionnaire II items (past year with portion size version). Patient-reported outcomes included self-reported lupus activity (Systemic Lupus Activity Questionnaire [SLAQ]). Multivariable regression, adjusted for age, sex, race, and body mass index, was used to assess associations between absolute intake of n-3 and n-6, as well as the n-6:n-3 ratio, and patient-reported outcomes. Results Among 456 SLE cases, 425 (93.2%) were female, 207 (45.4%) were African American, and the mean +/- SD age was 52.9 +/- 12.3 years. Controlling for potential confounders, the average SLAQ score was significantly higher by 0.3 points (95% confidence interval [95% CI] 0.1, 0.6;P= 0.013) with each unit increase of the n-6:n-3 ratio. Both lupus activity and Patient-Reported Outcomes Measurement Information System (PROMIS) sleep disturbance scores were lower with each 1-gram/1,000 kcal increase of n-3 fatty acids (SLAQ regression coefficient beta = -0.8 [95% CI -1.6, 0.0];P= 0.055; PROMIS sleep beta = -1.1 [95% CI -2.0, -0.2];P= 0.017). Higher n-3 intakes were nonsignificantly associated with lower levels of depressive symptoms and comorbid fibromyalgia, and with higher quality of life, whereas results for the n6:n3 ratio trended in the opposite direction. Conclusion This population-based study suggests that higher dietary intake of n-3 fatty acids and lower n-6:n-3 ratios are favorably associated with patient-reported outcomes in SLE, particularly self-reported lupus activity and sleep quality.
引用
收藏
页码:874 / 881
页数:8
相关论文
共 50 条
  • [21] Fatigue, health-related quality of life and other patient-reported outcomes in systemic lupus erythematosus
    Schmeding, A.
    Schneider, M.
    BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY, 2013, 27 (03): : 363 - 375
  • [22] Polyunsaturated omega-3 fatty acids and systemic lupus erythematosus: what do we know?
    Borges, Mariane Curado
    Moura Santos, Fabiana de Miranda
    Telles, Rosa Weiss
    Toulson Davisson Correia, Maria Isabel
    Duarte Lanna, Cristina Costa
    REVISTA BRASILEIRA DE REUMATOLOGIA, 2014, 54 (06) : 459 - 466
  • [23] Associations between physicians' global assessment of disease activity and patient-reported outcomes in patients with systemic lupus erythematosus: A longitudinal study
    Louthrenoo, Worawit
    Kasitanon, Nuntana
    Morand, Eric
    Kandane-Rathnayake, Rangi
    LUPUS, 2021, 30 (10) : 1586 - 1595
  • [24] The Impact of Asthma and Chronic Obstructive Pulmonary Disease (COPD) on Patient-Reported Outcomes in Systemic Lupus Erythematosus (SLE)
    Katz, Patricia
    Pedro, Sofia
    Trupin, Laura
    Yelin, Edward
    Michaud, Kaleb
    ACR OPEN RHEUMATOLOGY, 2021, 3 (04) : 221 - 230
  • [25] The effect of Omega-3 fatty acid supplementation in systemic lupus erythematosus patients: A systematic review
    Ramessar, Nina
    Borad, Abhilasha
    Schlesinger, Naomi
    LUPUS, 2022, 31 (03) : 287 - 296
  • [26] Possibilities and limits of patient-reported outcome exemplified by systemic lupus erythematosus and the LuLa study
    Chehab, G.
    Richter, J.
    Schneider, M.
    ZEITSCHRIFT FUR RHEUMATOLOGIE, 2014, 73 (08): : 698 - 705
  • [27] Major Depression and Adverse Patient-Reported Outcomes in Systemic Lupus Erythematosus: Results From a Prospective Longitudinal Cohort
    Dietz, Brett
    Katz, Patricia
    Dall'Era, Maria
    Murphy, Louise B.
    Lanata, Cristina
    Trupin, Laura
    Criswell, Lindsey A.
    Yazdany, Jinoos
    ARTHRITIS CARE & RESEARCH, 2021, 73 (01) : 48 - 54
  • [28] An exploration of patient-reported symptoms in systemic lupus erythematosus and the relationship to health-related quality of life
    Pettersson, S.
    Lovgren, M.
    Eriksson, L. E.
    Moberg, C.
    Svenungsson, E.
    Gunnarsson, I.
    Henriksson, E. Welin
    SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2012, 41 (05) : 383 - 390
  • [29] Fatigue, patient reported outcomes, and objective measurement of physical activity in systemic lupus erythematosus
    Mahieu, M. A.
    Ahn, G. E.
    Chmiel, J. S.
    Dunlop, D. D.
    Helenowski, I. B.
    Semanik, P.
    Song, J.
    Yount, S.
    Chang, R. W.
    Ramsey-Goldman, R.
    LUPUS, 2016, 25 (11) : 1190 - 1199
  • [30] Psychometric Evaluation of the National Institutes of Health Patient-Reported Outcomes Measurement Information System in a Multiracial, Multiethnic Systemic Lupus Erythematosus Cohort
    Katz, Patricia
    Yazdany, Jinoos
    Trupin, Laura
    Rush, Stephanie
    Helmick, Charles G.
    Murphy, Louise B.
    Lanata, Cristina
    Criswell, Lindsey A.
    Dall'Era, Maria
    ARTHRITIS CARE & RESEARCH, 2019, 71 (12) : 1630 - 1639